StockData

ANI Pharmaceuticals vs Harrow

ANIP and HROW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIP and HROW compare

ANI Pharmaceuticals is the larger company, worth 1.5 times as much as Harrow ($1.6B against $1.1B).

ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 21.1% for Harrow).

ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.1% compared with −13.5% at Harrow.

ANI Pharmaceuticals scores higher on the StockData Score (14 against 6 for Harrow), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIPHROW
Size and price
Market cap$1.6B$1.1B
Share price$70.89$29.09
Change, 1 year−16.2%−23.2%
Change, 5 years73.9%183%
Beta (5Y)0.632.11
Employees970373
StockData Score
Total score14 (better)6
Valuation score5 (better)0
Growth score23 (better)
Performance score4 (better)2
Health score3 (better)1
Dividend score00
Valuation
P/E15.1×–
P/S1.7× (better)4.0×
P/B2.7× (better)71.7×
EV/EBITDA6.6×–
P/FCF9.4× (better)217×
FCF yield10.6% (better)0.46%
Fair value$134.15–
Margin of safety47.2%–
Growth
Revenue growth (TTM)30.9% (better)21.1%
Revenue growth, 5Y average33.5%41.0% (better)
Profitability
Gross margin60.4%73.3% (better)
Operating margin15.4% (better)−1.00%
Net margin11.1% (better)−13.5%
FCF margin17.7% (better)1.8%
Return on equity21.0% (better)−115%
Return on invested capital21.3% (better)−1.7%
Financial health
Debt / equity0.50 (better)19.24
Net debt / EBITDA−0.25–
Interest coverage4.8× (better)−0.1×
Current ratio2.91 (better)2.24
Altman Z-score2.54 (better)1.96
Piotroski F-score7 (better)5
Dividends and buybacks
Payout ratio0.32%–
Buyback yield1.4%–
Shareholder yield1.4% (better)0.00%
Ownership
Held by institutions100%57.4%
Held by insiders12.3%14.2%
Insider net buying, 12 months−$13.6M−$9.2M (better)
Short interest, % of float17.8%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.